Brokerages expect Omnicell, Inc. (NASDAQ:OMCL) to report earnings of $0.41 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Omnicell’s earnings, with the lowest EPS estimate coming in at $0.40 and the highest estimate coming in at $0.41. Omnicell reported earnings per share of $0.29 during the same quarter last year, which indicates a positive year-over-year growth rate of 41.4%. The company is scheduled to announce its next earnings report on Thursday, April 25th.
On average, analysts expect that Omnicell will report full year earnings of $2.52 per share for the current year, with EPS estimates ranging from $2.48 to $2.55. For the next fiscal year, analysts anticipate that the firm will post earnings of $2.86 per share, with EPS estimates ranging from $2.78 to $2.90. Zacks’ EPS averages are an average based on a survey of analysts that cover Omnicell.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 7th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.16. Omnicell had a return on equity of 9.31% and a net margin of 4.79%. The business had revenue of $211.75 million during the quarter, compared to analysts’ expectations of $215.41 million. During the same period in the previous year, the firm earned $0.55 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year.
In other Omnicell news, Chairman Randall A. Lipps sold 20,000 shares of the business’s stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $85.54, for a total value of $1,710,800.00. Following the completion of the transaction, the chairman now directly owns 194,793 shares of the company’s stock, valued at $16,662,593.22. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Dan S. Johnston sold 8,210 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $81.16, for a total value of $666,323.60. Following the completion of the transaction, the executive vice president now directly owns 36,504 shares of the company’s stock, valued at $2,962,664.64. The disclosure for this sale can be found here. Over the last three months, insiders sold 88,982 shares of company stock valued at $7,389,181. Insiders own 2.77% of the company’s stock.
A number of large investors have recently bought and sold shares of OMCL. Bank of New York Mellon Corp grew its holdings in shares of Omnicell by 2.5% during the third quarter. Bank of New York Mellon Corp now owns 946,239 shares of the company’s stock valued at $68,035,000 after buying an additional 22,890 shares during the last quarter. BlackRock Inc. raised its position in Omnicell by 5.9% in the third quarter. BlackRock Inc. now owns 5,903,099 shares of the company’s stock worth $424,432,000 after acquiring an additional 327,747 shares during the period. American International Group Inc. raised its position in Omnicell by 2.9% in the third quarter. American International Group Inc. now owns 30,486 shares of the company’s stock worth $2,192,000 after acquiring an additional 873 shares during the period. Allianz Asset Management GmbH raised its position in Omnicell by 518.9% in the third quarter. Allianz Asset Management GmbH now owns 124,170 shares of the company’s stock worth $8,928,000 after acquiring an additional 104,107 shares during the period. Finally, Riverhead Capital Management LLC raised its position in Omnicell by 34.5% in the third quarter. Riverhead Capital Management LLC now owns 7,400 shares of the company’s stock worth $532,000 after acquiring an additional 1,900 shares during the period. 97.25% of the stock is owned by hedge funds and other institutional investors.
Shares of Omnicell stock traded down $6.14 during trading on Wednesday, reaching $71.67. 673,034 shares of the company were exchanged, compared to its average volume of 330,598. The company has a quick ratio of 1.45, a current ratio of 1.94 and a debt-to-equity ratio of 0.20. Omnicell has a twelve month low of $42.01 and a twelve month high of $86.87. The stock has a market cap of $3.14 billion, a PE ratio of 46.84, a price-to-earnings-growth ratio of 3.77 and a beta of 1.23.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Recommended Story: Book Value Per Share – BVPS
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.